Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Crowley

Showing results (111-120 of 178) with videos related to

Pageof 18
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 4, 2008
The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung CancerWilliam D Travis, Dorothy J Giroux, Kari Chansky, et al.
Blood|October 23, 2013
Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)Madhav V Dhodapkar, Rachael Sexton, Sarah Waheed, et al.
Haematologica|June 13, 2012
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agentsSaad Z Usmani, Christoph Heuck, Alan Mitchell, et al.
Blood|May 27, 2008
First thalidomide clinical trial in multiple myeloma: a decadeFrits van Rhee, Madhav Dhodapkar, John D Shaughnessy, et al.
British Journal of Haematology|December 13, 2006
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering diseaseMauricio Pineda-Roman, Vanessa Bolejack, Varant Arzoumanian, et al.
British Journal of Haematology|July 23, 2009
Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myelomaSundar Jagannath, Brian G M Durie, Jeffrey Lee Wolf, et al.
Blood|May 16, 2009
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myelomaTwyla B Bartel, Jeff Haessler, Tracy L Y Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2007
Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160)Valerie W Rusch, Dorothy J Giroux, Michael J Kraut, et al.
Blood Cancer Journal|July 8, 2018
Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trialsSikander Ailawadhi, Susanna Jacobus, Rachael Sexton, et al.
Biotechnology and Bioengineering|March 12, 2020
Beyond heuristics: CFD-based novel multiparameter scale-up for geometrically disparate bioreactors demonstrated at industrial 2kL-10kL scalesJames Scully, Laura B Considine, Mark T Smith, et al.
Pageof 18

Showing results (111-120 of 178) with videos related to

Sort By:
Pageof 18
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 4, 2008
The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung CancerWilliam D Travis, Dorothy J Giroux, Kari Chansky, et al.
Blood|October 23, 2013
Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)Madhav V Dhodapkar, Rachael Sexton, Sarah Waheed, et al.
Haematologica|June 13, 2012
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agentsSaad Z Usmani, Christoph Heuck, Alan Mitchell, et al.
Blood|May 27, 2008
First thalidomide clinical trial in multiple myeloma: a decadeFrits van Rhee, Madhav Dhodapkar, John D Shaughnessy, et al.
British Journal of Haematology|December 13, 2006
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering diseaseMauricio Pineda-Roman, Vanessa Bolejack, Varant Arzoumanian, et al.
British Journal of Haematology|July 23, 2009
Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myelomaSundar Jagannath, Brian G M Durie, Jeffrey Lee Wolf, et al.
Blood|May 16, 2009
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myelomaTwyla B Bartel, Jeff Haessler, Tracy L Y Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2007
Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160)Valerie W Rusch, Dorothy J Giroux, Michael J Kraut, et al.
Blood Cancer Journal|July 8, 2018
Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trialsSikander Ailawadhi, Susanna Jacobus, Rachael Sexton, et al.
Biotechnology and Bioengineering|March 12, 2020
Beyond heuristics: CFD-based novel multiparameter scale-up for geometrically disparate bioreactors demonstrated at industrial 2kL-10kL scalesJames Scully, Laura B Considine, Mark T Smith, et al.
Pageof 18